The future role of mitochondrial drugs in vascularized composite allotransplantation: A short review
Vascularized composite allotransplantation (VCA) has emerged as an innovative strategy to restore form and function in patients with severe tissue defects involving anatomical regions such as the face, hand, and abdominal wall. Composite allografts are composed of diverse tissues, including skin, mu...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-08-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.1177/09636897251347749 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849390578020646912 |
|---|---|
| author | Leonard Knoedler Daniel H. Mendelsohn Loïc Van Dieren Thomas Schaschinger Cosima C. Hoch Max Heiland Jasper Iske Felix J. Klimitz Maxime Jeljeli Korkut Uygun Curtis L. Cetrulo Alexandre G. Lellouch |
| author_facet | Leonard Knoedler Daniel H. Mendelsohn Loïc Van Dieren Thomas Schaschinger Cosima C. Hoch Max Heiland Jasper Iske Felix J. Klimitz Maxime Jeljeli Korkut Uygun Curtis L. Cetrulo Alexandre G. Lellouch |
| author_sort | Leonard Knoedler |
| collection | DOAJ |
| description | Vascularized composite allotransplantation (VCA) has emerged as an innovative strategy to restore form and function in patients with severe tissue defects involving anatomical regions such as the face, hand, and abdominal wall. Composite allografts are composed of diverse tissues, including skin, muscle, bone, vasculature, nerves, and mucosal surfaces, posing unique challenges in immunological management. Clinical outcomes following VCA surgeries have been encouraging; however, a comprehensive understanding of the underlying cellular interactions and molecular pathways is still predominantly derived from studies in solid organ transplantation (SOT). Recent advances in SOT have identified mitochondria as crucial therapeutic targets capable of mediating transplant rejection, mitigating ischemia-reperfusion injury (IRI), and enhancing graft longevity. Nevertheless, the explicit role and potential therapeutic applications of mitochondria within VCA remain largely unexplored. This review aims to critically examine and elucidate the significance of mitochondria in overcoming the current limitations encountered in VCA surgery. A deeper insight into mitochondrial biology could hypothetically provide clinicians and researchers with novel, targeted therapeutic strategies to improve clinical outcomes in VCA; however, these approaches require further validation in preclinical models. |
| format | Article |
| id | doaj-art-908b0ef413de40f5a55e852a82a90f90 |
| institution | Kabale University |
| issn | 1555-3892 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cell Transplantation |
| spelling | doaj-art-908b0ef413de40f5a55e852a82a90f902025-08-20T03:41:31ZengSAGE PublishingCell Transplantation1555-38922025-08-013410.1177/09636897251347749The future role of mitochondrial drugs in vascularized composite allotransplantation: A short reviewLeonard Knoedler0Daniel H. Mendelsohn1Loïc Van Dieren2Thomas Schaschinger3Cosima C. Hoch4Max Heiland5Jasper Iske6Felix J. Klimitz7Maxime Jeljeli8Korkut Uygun9Curtis L. Cetrulo10Alexandre G. Lellouch11Department of Oral and Maxillofacial Surgery, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyInstitute of Pathology, Medical Faculty Mannheim, Heidelberg University, Mannheim, GermanyVascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USADepartment of Oral and Maxillofacial Surgery, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyDepartment of Otolaryngology, Head and Neck Surgery, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, GermanyDepartment of Oral and Maxillofacial Surgery, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, GermanyDepartment of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité, Berlin, GermanyDivision of Plastic Surgery, Yale School of Medicine, Department of Surgery, New Haven, CT, USADepartment of Plastic, Reconstructive and Aesthetic Surgery, Cedars Sinai Hospital, Los Angeles, USAShriners Hospitals for Children, Boston, MA, USADepartment of Plastic, Reconstructive and Aesthetic Surgery, Cedars Sinai Hospital, Los Angeles, USAHematology department, Hôpital Européen Georges Pompidou, Université Paris Cité (2- AP-HP), Paris, FranceVascularized composite allotransplantation (VCA) has emerged as an innovative strategy to restore form and function in patients with severe tissue defects involving anatomical regions such as the face, hand, and abdominal wall. Composite allografts are composed of diverse tissues, including skin, muscle, bone, vasculature, nerves, and mucosal surfaces, posing unique challenges in immunological management. Clinical outcomes following VCA surgeries have been encouraging; however, a comprehensive understanding of the underlying cellular interactions and molecular pathways is still predominantly derived from studies in solid organ transplantation (SOT). Recent advances in SOT have identified mitochondria as crucial therapeutic targets capable of mediating transplant rejection, mitigating ischemia-reperfusion injury (IRI), and enhancing graft longevity. Nevertheless, the explicit role and potential therapeutic applications of mitochondria within VCA remain largely unexplored. This review aims to critically examine and elucidate the significance of mitochondria in overcoming the current limitations encountered in VCA surgery. A deeper insight into mitochondrial biology could hypothetically provide clinicians and researchers with novel, targeted therapeutic strategies to improve clinical outcomes in VCA; however, these approaches require further validation in preclinical models.https://doi.org/10.1177/09636897251347749 |
| spellingShingle | Leonard Knoedler Daniel H. Mendelsohn Loïc Van Dieren Thomas Schaschinger Cosima C. Hoch Max Heiland Jasper Iske Felix J. Klimitz Maxime Jeljeli Korkut Uygun Curtis L. Cetrulo Alexandre G. Lellouch The future role of mitochondrial drugs in vascularized composite allotransplantation: A short review Cell Transplantation |
| title | The future role of mitochondrial drugs in vascularized composite allotransplantation: A short review |
| title_full | The future role of mitochondrial drugs in vascularized composite allotransplantation: A short review |
| title_fullStr | The future role of mitochondrial drugs in vascularized composite allotransplantation: A short review |
| title_full_unstemmed | The future role of mitochondrial drugs in vascularized composite allotransplantation: A short review |
| title_short | The future role of mitochondrial drugs in vascularized composite allotransplantation: A short review |
| title_sort | future role of mitochondrial drugs in vascularized composite allotransplantation a short review |
| url | https://doi.org/10.1177/09636897251347749 |
| work_keys_str_mv | AT leonardknoedler thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT danielhmendelsohn thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT loicvandieren thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT thomasschaschinger thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT cosimachoch thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT maxheiland thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT jasperiske thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT felixjklimitz thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT maximejeljeli thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT korkutuygun thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT curtislcetrulo thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT alexandreglellouch thefutureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT leonardknoedler futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT danielhmendelsohn futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT loicvandieren futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT thomasschaschinger futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT cosimachoch futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT maxheiland futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT jasperiske futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT felixjklimitz futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT maximejeljeli futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT korkutuygun futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT curtislcetrulo futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview AT alexandreglellouch futureroleofmitochondrialdrugsinvascularizedcompositeallotransplantationashortreview |